Assess whether RWE can replace or only supplement an RCT (6eb8dd)
August 31, 2026 · SmartSolo
Situation
The Pharmacovigilance desk packet is 505(b)(2) literature-to-product bridge table after an inspector asking for batch records you cannot produce this week. Clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study must name RWE can replace or Only supplement an RCT for this Pharma & Life Sciences file. Clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study has to name RWE can replace or Only supplement an RCT for this Pharma & Life Sciences Pharmacovigilance file.
Decision
Clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study must choose RWE can replace / Only supplement an RCT using 505(b)(2) literature-to-product bridge table after an inspector asking for batch records you cannot produce this week.
Hypotheses to test
- Authorize RWE can replace now; 505(b)(2) literature-to-product bridge table already has the discriminator after an inspector asking for batch records you cannot produce this week.
- Keep Only supplement an RCT in force until 505(b)(2) literature-to-product bridge table is completed after an inspector asking for batch records you cannot produce this week for clinical-development physician.
- Treat 505(b)(2) literature-to-product bridge table as RWE can replace because both readings appear after an inspector asking for batch records you cannot produce this week.
- Refuse a Pharma & Life Sciences close: clinical-development physician does not have the page RWE can replace or turns on in 505(b)(2) literature-to-product bridge table.
Analysis required
- Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim clinical-development physician would keep.
- Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
- Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after an inspector asking for batch records you cannot produce this week.
- For this Pharma & Life Sciences Pharmacovigilance file, read 505(b)(2) literature-to-product bridge table against an inspector asking for batch records you cannot produce this week and write the one fact that would move RWE can replace or for clinical-development physician.
Recommendation
Explore more
More Pharma & Life Sciences prompts
- Assess whether to drop a secondary endpoint that will dominate the AdCom
- Assess whether scientific advice should be sought before the next trial
- Assess whether a CMO finding is a delay or a refuse-to-file risk (303406)
- Assess whether the primary endpoint will survive FDA scrutiny (43bc53)
- Assess whether the 505(b)(2) bridge is legally and scientifically enough
Explore related decision areas
See governed multi-model AI on your own prompt
Compare GPT-5, Claude, and Gemini side by side, with human review and a decision record built in.

